Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review
- 23 May 2025
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (12) , 101948
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- 195P Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancerAnnals of Oncology, 2024
- Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Advances in Therapy, 2024
- HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapyGynecologic Oncology, 2022
- Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neuGynecologic Oncology, 2021
- Therapeutic options for mucinous ovarian carcinomaGynecologic Oncology, 2020
- Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancerGynecologic Oncology, 2012
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- Amplification of c‐erbB2 oncogeneCancer, 2005